{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:05:52Z","timestamp":1792699552347,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["AI059374"],"award-info":[{"award-number":["AI059374"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006377","name":"Purdue University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012321","name":"College of Veterinary Medicine, Auburn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.omtm.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T14:46:49Z","timestamp":1531838809000},"page":"210-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose"],"prefix":"10.1016","volume":"10","author":[{"given":"Ekramy E.","family":"Sayedahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaprakash","family":"Gangappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryaprakash","family":"Sambhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2018.07.007_bib1","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/156652311796150372","article-title":"Adenoviral vector immunity: its implications and circumvention strategies","volume":"11","author":"Ahi","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib3","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/gt.2010.1","article-title":"Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses","volume":"17","author":"Sharma","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virusres.2004.05.003","article-title":"Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture","volume":"105","author":"Bangari","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.omtm.2018.07.007_bib6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.omtm.2018.07.007_bib7","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5\u00a0and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.omtm.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of nonhuman adenoviruses as vaccine vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2018.07.007_bib9","series-title":"Adenoviral Vectors for Gene Therapy","first-page":"495","article-title":"Xenogenic adenoviral vectors A2","author":"Mittal","year":"2016"},{"key":"10.1016\/j.omtm.2018.07.007_bib10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2008.12","article-title":"Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus","volume":"16","author":"Singh","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbrc.2004.12.099","article-title":"Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture","volume":"327","author":"Bangari","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtm.2018.07.007_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2009.01.008","article-title":"Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model","volume":"386","author":"Sharma","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2018.07.007_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.virusres.2011.08.002","article-title":"Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines","volume":"161","author":"Sharma","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.omtm.2018.07.007_bib14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.bbrc.2005.04.058","article-title":"Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3","volume":"331","author":"Bangari","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtm.2018.07.007_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.virol.2009.06.029","article-title":"Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry","volume":"392","author":"Li","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2018.07.007_bib16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/529522","article-title":"A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses","volume":"197","author":"Hoelscher","year":"2008","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2018.07.007_bib17","doi-asserted-by":"crossref","first-page":"e62496","DOI":"10.1371\/journal.pone.0062496","article-title":"Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness","volume":"8","author":"Vemula","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2018.07.007_bib18","unstructured":"Gene Therapy Clinical Trials Worldwide. (2017). Vectors used in gene therapy clinical trials. http:\/\/www.abedia.com\/wiley\/vectors.php."},{"key":"10.1016\/j.omtm.2018.07.007_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtm.2018.07.007_bib20","doi-asserted-by":"crossref","first-page":"e0005527","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.omtm.2018.07.007_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp100219n","article-title":"Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data","volume":"8","author":"Pesonen","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtm.2018.07.007_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/hum.2005.16.281","article-title":"Good manufacturing practice production of adenoviral vectors for clinical trials","volume":"16","author":"Lusky","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.biotechadv.2008.10.003","article-title":"From the first to the third generation adenoviral vector: what parameters are governing the production yield?","volume":"27","author":"Dormond","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.omtm.2018.07.007_bib24","first-page":"175","article-title":"Scalable production of adenovirus vectors","volume":"Volume 1089","author":"Silva","year":"2014"},{"key":"10.1016\/j.omtm.2018.07.007_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2018.07.007_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.clpt.6100418","article-title":"New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice","volume":"82","author":"Hoelscher","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.virusres.2013.09.013","article-title":"Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time","volume":"178","author":"Vemula","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.omtm.2018.07.007_bib28","doi-asserted-by":"crossref","first-page":"e0186244","DOI":"10.1371\/journal.pone.0186244","article-title":"Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses","volume":"12","author":"Hassan","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2018.07.007_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3201\/eid1201.051237","article-title":"Cell-mediated protection in influenza infection","volume":"12","author":"Thomas","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.omtm.2018.07.007_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/JVI.80.4.1959-1964.2006","article-title":"Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization","volume":"80","author":"Gao","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2018.07.007_bib32","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/259679a0","article-title":"Unrelated animal viruses share receptors","volume":"259","author":"Lonberg-Holm","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2018.07.007_bib34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.omtm.2018.07.007_bib35","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1128\/JVI.76.12.5882-5892.2002","article-title":"Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted","volume":"76","author":"van Olphen","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.cgt.7700761","article-title":"Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1","volume":"11","author":"Noblitt","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtm.2018.07.007_bib38","doi-asserted-by":"crossref","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","article-title":"Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine","volume":"7","author":"Pandey","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2018.07.007_bib39","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1099\/0022-1317-78-11-2933","article-title":"Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection","volume":"78","author":"Papp","year":"1997","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omtm.2018.07.007_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/viro.2002.1389","article-title":"Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines","volume":"295","author":"van Olphen","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2018.07.007_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/viro.1995.1553","article-title":"Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus)","volume":"213","author":"Mittal","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2018.07.007_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0264-410X(00)00170-5","article-title":"Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response","volume":"19","author":"Mittal","year":"2000","journal-title":"Vaccine"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118300706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118300706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:21:11Z","timestamp":1762420871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050118300706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"alternative-id":["S2329050118300706"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2018.07.007","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Purdue University.","name":"copyright","label":"Copyright"}]}}